News about Global Pharma

AbbVie Files US FDA BLA for Etentamig in Multiple Myeloma

AbbVie has submitted Biologics License Application (BLA) for Etentamig to US FDA for adults living with Relapsed/Refractory Multiple Myeloma (RRMM).

Global Pharma | 03/11/2026 | By News Bureau |  100

Cumberland Pharma Plans Ifetroban NDA for DMD

Cumberland Pharmaceuticals has announced plans to file New Drug Application (NDA) for ifetroban DMD program.

Global Pharma | 28/10/2026 | By News Bureau

Innovent Announces NMPA Acceptance of New Indication Application of Sintilimab

Innovent’s sintilimab application for advanced melanoma is accepted by China’s NMPA, supported by results from the pivotal phase 2 MIZAR-003 clinical study.

Global Pharma | 27/10/2026 | By News Bureau |  106

J&J Reports 75 Percent Tumor Response with JNJ-6143 in Prostate Cancer

Johnson & Johnson has reported 75 percent tumor response rate in advanced prostate cancer with JNJ-6143, a first-in-class RIPTAC molecule.

Global Pharma | 27/10/2026 | By News Bureau |  121

China Approves Harbour BioMed's Batoclimab for Myasthenia Gravis

Harbour BioMed has received China NMPA approval of Batoclimab Injection (subcutaneous injection) for the treatment of generalised Myasthenia Gravis.

Global Pharma | 26/10/2026 | By News Bureau |  114

Rznomics' RZ-001 Gets EU Orphan Drug Designation for Glioma

Rznomics has received European Commission (EC) orphan medicinal product designation for RZ-001, supporting its development as a potential treatment for glioma.

Global Pharma | 22/10/2026 | By News Bureau |  137

GSK to Showcase Oncology Pipeline Data at ESMO 2026

GSK to present more than 20 oncology abstracts at ESMO 2026, highlighting clinical research across several difficult-to-treat solid tumours.

Global Pharma | 19/10/2026 | By News Bureau |  210

EMA Recommends Lilly's Foundayo for Weight Management

Eli Lilly’s Foundayo has received an EMA recommendation for marketing authorisation as an oral GLP-1 medicine for weight management and Type 2 Diabetes.

Global Pharma | 19/10/2026 | By News Bureau |  112

US FDA Approves Viatris' RYZUMVI for Presbyopia

Viatris has received US FDA approval for RYZUMVI to treat presbyopia. The eye drop is already approved in the US for pharmacologically induced mydriasis.

Global Pharma | 19/10/2026 | By News Bureau

US FDA Approves OTC Eye Drops to Relieve Eye Redness

The US FDA has approved the first non prescription eye drop containing apraclonidine to provide relief from eye redness.

Global Pharma | 17/10/2026 | By News Bureau |  117